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Multistage Models for Carcinogenesis
by David A. Freedman* and William C. Navidit
The multistage model is testedon several human and animal data sets. It fits in some cases but not in others.
With human lung cancer data, there is a drop in risk for ex-smokers quite different from the predictions of
the model. The results are not conclusive but are compatible with the view that the multistage model pro-
vides a family ofcurves that often fit cancer incidence data, but may not capture the underlying biological
reality.
Introduction
The Armitage-Doll multistage model says in essence
that a cell progresses to malignancy through the states
of a Markov chain (1). This model is often used in cancer
risk assessment for example, by the U.S. Environmental
Protection Agency (2), and itis often cited in discussions
ofthebiologicalmechanisms ofcancer, forexample, bythe
International Agencyfor Research onCancer(3). Itthere-
fore seems worthwhile to review the model and assess its
fit to some of the main available data sets, which is the
object of the present paper.
Tb state the model a bit more carefully (4-6): A normal
cell goes through a definite sequence ofstages until it be-
comes cancerous. Absent carcinogenic exposure, waiting
times in the various stages are assumed to be indepen-
dent, exponential random variables. So, there is a back-
groundrate ofprogression througheach stage, which may
be different for the different stages.
An animal or a human tissue is a collection ofcells and
fails (gets cancer)when the first cell inthe collection fails.
Thus, the failure time forthe tissue isthe minimum ofthe
failure times ofits component cells. Different cells are as-
sumed to be independent with identically distributed fail-
ure times.
The next assumption: If a subject is exposed to a car-
cinogen such as tobacco smoke, the rate of progression
through the various stages increases in proportion to
dose; the constant of proportionality depends on the
stage. For the insensitive stages, this constant is zero; for
the sensitive stages, the constant of proportionality is
positive. Stages that may be estimated as sensitive or in-
sensitive, depending on how the data turn out, will be
termed "potentially sensitive?'
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Inorderforthe usual approximations towork, itis also
necessary to assumethatthe time topassthrough a stage
tends to be much larger than the lifetime of the animal
(7). The rates ofprogression through the various stages
are assumed to be the same for all cells and all subjects.
In risk assessment, constancy ofcertain rates is assumed
even across species.
With a final assumption, independence of competing
risks, the model canbe usedtogenerate alikelihoodfunc-
tion for data; parameters can be estimated by maximum
likelihood. Then the adequacy ofthe fit can be assessed
by a chi-squared test. The intent was to follow this
strategy rigorously, but we ended up making some ap-
proximations for mathematical convenience, others to get
numerical algorithms to converge, and still others to ac-
commodate experimental designs.
In a strictmodelingapproach, the detailsbecome quite
irritating. Perhaps as a result, most published efforts to
assess the fit ofthe model tend to involve simple approx-
imations to the likelihood function, and goodness-of-fit
tests are seldom made (8-11). On the other hand, the
statistical strategy followed here is similar to that in
Brown and Hoel (12-13).
There are many variations on the model, for example,
allowing a latency period between malignancy and the
clinically observable endpoint. Polynomial dose response
at each stage has also been considered and transitions
from higher order to lower order states. Dose thresholds
are sometimes used ornonlinear transformations oftime.
Random parameters are another option. There is little
doubt that, given a data set, one variation on the model
oranother canbe made tofit. Ourquestion runs the other
wayround: Given aversion ofthe model, will itfit a vari-
ety of data sets? For that purpose, we elected to start
with the version described here, which is relatively sim-
ple and in general circulation.
Versions of the model are widely used in risk assess-
ment, although theirbiological basisis more than a little
obscure. Inparticular, despite remarkableprogress ontheFREEDMAN AND NAVIDI
Table 1. Summary of results.
Data set Species End point Results
British doctors Humans Lung cancer Fits; 5-8 stages; one or two
sensitive; heavy smokers
included
Veterans Humans Lung cancer Does not fit: p = 5/100,000
ACS Human males Lung cancer Marginal fit; p = 1% 6 stages
with 1st sensitive, or 7 stages
with 6th sensitive fails on
cross-validation
Human females Lung cancer Fits; 3 to 8 stages; one sensitive
Mega-mouse Mice Bladder tumors Does not fit
Liver tumors Fits; 7 stages, 2 sensitive
Peto et al. Mice Skin cancer Does not fit
identification ofDNA lesions in tumor cells, there is still
no experimental verification of the assumptions in the
multistage model at the level of the cell. For example,
there is no general biological definition for the stages in
the model; in most cases, these remain purely hypotheti-
cal constructs (5,14-18). Striking recent papers on the
genetics of cancer include Bodmer et al. (19), Naylor et
al. (20), and Solomon et al. (21).
Results
Overview
This section will review the data sets considered and
summarize conclusions (Table 1). The most carefully
studied application ofthe model is to lung cancer, which
is considered first; then comes experimental data on
animals.
OtherFindings onLung Cancer. For the British doc-
tors, the Dorn veterans, and the ACS males, the model
overpredicts around the edges of the data set. Models
fitted to continuing smokers do notpredicttheriskforex-
smokers at all well: The models predict that excess risk
will continue to increase (or stay constant) afterquitting,
while the data show a decrease.
Human Lung Cancer
British Doctors. Doll and Peto report on smoking and
lung cancer in their seminal cohort study ofBritish doc-
tors (9). The data quality is considered to be excellent;
dose was ascertained on three separate occasions. One
drawback is the absence ofinformation on age at start of
smoking; following Doll and Peto, this is imputed as 22.5
years(including some allowance forthe time frommalig-
nancy to death). Furthermore, although the study lasted
20years with about 34,000 subjects, the numberofevents
(lung cancer cases) is relatively small.
The data set used here, reported in Doll and Peto (9),
selects only subjects who smoked at a nearly constant
rate; only 215 events out of571 are kept. The published
data on ex-smokers are not in usable form and the unpub-
lished data do not appear to be available.
Data on nonsmokers or current smokers are summa-
rized. For this cohort, there is a paradoxical drop in risk
(eventsper 1000person years)for the highest dosegroup
and at the highest ages. This is more readily seen from
Doll and Peto's table than from our aggregation (Thbles
2 and 3).
A variety of models fit quite well, with five to eight
stages; models withfour ornine stages did notfit. Previ-
ous work suggests five or six as the number of stages.
(The plural "models" refers to special cases ofthe singu-
lar "multistage model.")
Is the dose response linear or quadratic? In the mul-
tistage model, this comes down to askingwhether there
is one sensitive stage ortwo. This question hasbeenmuch
debated. In ourmodels, withfive, six, or seven stages, the
first and next-to-last appear to be sensitive. With eight
stages, the first need not be sensitive. We view the data
on the British doctors as compatible with a linear or a
quadratic dose response; the latter provides a signifi-
cantlybetter fit. (Forthe veterans orthe ACS volunteers,
a linear dose response fits about as well, or as badly, as
quadratic.)
We allow eitherthe first and next-to-last stages, orthe
first and last, to be sensitive. Both types ofmodels give
similar fits on current smokers, but make very different
predictions for ex-smokers. The conventional choice is to
allow the first and next-to-last stagestobe sensitive (22).
When suchmodels arefittedto the continuingsmokers,
thefirst stageusually turns out to be sensitive, andthen
the model predicts that the excess risk will continue to
rise aftercessation ofsmoking(Eq. 3). The rate ofrise is
quite appreciable. It is commonlybelieved, however, that
the excess risk remains constant after cessation of ex-
posure. This beliefand the model do notfittogether. Fur-
thermore, the data suggest that the risk starts to drop on
cessation of smoking.
Comingback to the continuing smokers, Doll and Peto
(9) found it necessary to exclude the heavy smokers and
gave ingenious arguments based on measurement error
to justify the exclusion. They fit an appealing (but non-
multistage) model. Workingfairly directly from the likeli-
hoodfunctiongivenby themodel, thefitisgoodwhether
the heavy smokers are kept in or not. The tables include
the heavy smokers and abroader age range than that al-
lowedby Doll and Peto (25-84years). On the otherhand,
different parts ofthe data set do look different: A model
fitted to the data used by Doll and Peto (age 40-79, dose
40 or less) overpredicts risk for the rest.
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lible 2. The British doctors: Events/person years.a
Dose, cigarettes/day, range and (mean)
Age, 1-4 5-9 10-14 15-19 20-24 25-29 30-34 35-40 40+
years 0 (2.7) (6.6) (11.3) (16.0) (20.4) (25.4) (30.2) (38.0) (50.9)
20-24 0/378 0/19.5 0/38 0/91.5 0/91 0/57 0/7.5 0/2 0/2.5 0/0
25-29 0/5099.5 0/400 0/701.5 0/1529 0/1427 0/1424 0/304.5 0/153 0/46 0/10.5
30-34 0/10838 0/914 0/1762.5 0/3270 0/3343 0/3966.5 0/1042.5 0/582.5 0/224.5 0/32.5
35-39 1/15105 0/1156.5 0/2178 0/3819.5 0/4649.5 0/6003.5 0/1991.5 0/1108.5 0/545.5 0/110.5
40-44 0/17846.5 0/1216 0/2041.5 1/3795.5 0/4824 1/7046 0/2523 1/1715.5 0/892.5 0/234
45-49 0/15832.5 0/1000.5 0/1745 1/3205 1/3995 1/6460.5 2/2565.5 2/2123 0/1150 0/305.5
50-54 1/12226 0/853.5 0/1562.5 2/2727 4/3278.5 6/5583 3/2620 3/2226.5 3/1281 0/335.5
55-59 2/8905.5 1/625 0/1355 1/2288 0/2466.5 8/4357.5 5/2108.5 6/1923 4/1063 1/284
60-64 0/6248 1/509.5 1/1068 1/1714 2/1829.5 13/2863.5 4/1508.5 11/1362 7/826 1/183.5
65-69 0/4351 0/392.5 1/843.5 2/1214 2/1237 12/1930 5/974.5 9/763.5 9/515 1/120
70-74 1/2723.5 1/242 2/696.5 4/862 4/683.5 10/1055 7/527 2/317.5 5/233 2/52
75-79 2/1772 0/208.5 0/517.5 4/547 5/370.5 7/512 4/209.5 2/130 2/88.5 0/18.5
80-84 0/1185.5 0/173 0/281 1/314 1/180.5 1/188 0/81 2/37 1/36 0/2.5
85+ 0/870.5 0/77.5 0/149 0/123.5 1/61.5 1/67.5 0/28 0/1 0/.5 0/0
aReproduced from Doll and Peto (9). Doll and Peto use the data inside the smaller box; we use the data in the larger box.
Table 3. The British doctors: Events/person years, aggregation ofthe data from Table 2.'
Dose, cigarettes per day
Age 0 1-9 10-19 20-29 30-40 41 or more
54 or less 2/76,948 0/15,532 9/39,863 13/41,530 9/12,048 0/1,028
55 to 64 2/15,154 3/3,558 4/8,298 30/10,838 28/5,174 2/468
65 to 74 1/7,074 4/2,174 12/3,996 34/4,486 . 25/1,829 3/172
75 or more 2/2,958 0/1,180 11/1,412 12/990 7/292 0/21
aAge range 25 to 84 years; heavy smokers included.
Dorn Veterans. Kahn (23) reports on Dorn's cohort
studyofabout300,000Americanveterans, begunin 1954;
also see Rogot (24) and Whittemore (25). The data used
here come from a tape supplied in 1981 by the National
Cancer Institute (NCI) under the Freedom of Informa-
tion Act. This tape combines the 1954 and 1957 cohorts,
reports on follow-up through 1969, and has been edited
by NCI personnel. Data on the tape therefore differfrom
tables in Kahn (23).
The dataqualitymaybe questioned; inparticular, dose
was ascertained only once. On the positiveside, this data
setis quite large (1266events); it has information on age
at start ofsmoking and it includes ex-smokers. The risk
for current smokers increases with dose.
This data set is sometimes cited as supporting the
model (10). However, as far as we can see, no version of
themodelfits the veterans data. Fornonsmokers and cur-
rent smokers, the besthad six stages, with onlythe fifth
being sensitive: X2 = 50 on 17 degrees offreedom, p =
5/100,000. Residuals (observed - expected) were quite
regular, tending to be negative at the lowest or highest
age and dose groups, positive at intermediate groups.
When this model was used to predict the risk for ex-
smokers as afunction ofyears since quitting, the ratio of
observed to expected decreased steadily: Indeed, the ex-
cess risk in the model remains constant, while the data
show a drop in risk.
ACS Volunteers. This study is describedby Hammond
(26). L. Garfinkel ofthe ACS provided a table ofperson-
years and events for current smokers over the period July
1960 to June 1965, by age, age at start ofsmoking, dose,
and sex. (The table differs in some respects from pub-
lished data.) This is the only study with substantial num-
bers ofwomen. Because ofthe large number ofsubjects
(about 440,000 men and 570,000 women) there are alot of
events: 1542 for the male smokers, 164 for the females.
The men smoked more heavily than the women and had
higher cancer rates even controlling for smoking.
The data quality seemsgood. Theriskfor smokersgoes
up with dose. There is some deficit in events beyond age
79. This can be detected in the original data, butgetslost
in the aggregated Thble 10. The increased risk for ages
75 to 79 swamps the decrease in ages 80 and beyond,
where the number of person-years is relatively small.
For current male smokers, models with 3 to 10 stages
were tried. The best-fitting had 6 stages (X2 = 28 on 13
degrees offreedom, p = 1%); the estimated sensitivity for
the fifth stage was negligible. Compared to 1542 events,
the fit seems good. However, the pattern ofresiduals was
as in the veterans study. Rates for the nonsmokers, esti-
mated from the current smokers through the model, were
much higher than the observed rates. Largely by acci-
dent, we got the data on never-smokers or ex-smokers
only after fitting the models, so there was a genuine op-
portunity for cross-validation.
For currentfemale smokers, avariety ofmodels fit, with
three to eight stages; the best was five stages; almost any
pattern of sensitivity is obtainable. Estimated back-
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groundrates are unreasonably low; indeed, suchrates can
be constrained to zero without any trouble.
Animal Data Sets
Withhumanlungcancerdata, dosimetry isproblematic;
the accuracy ofdiagnosis is open to question too. Inprin-
ciple, experimental data on animals should be better. Of
course, animal experiments have problems oftheir own
(16). Perhaps surprisingly, it is not so easy to get animal
data suitable for testingmultistage models. Inparticular,
data on times of tumors are seldom published. (The
NCI/NTP bioassays might be a good data source, if
properly pooled.)
Mega-Mouse Study. This experiment is described by
Staffa and Mehlman (27); see especially Littlefield et al.
(28). The experiment involved about24,000mice; the car-
cinogen was 2-acetylaminofluorene (2-AAF); bladder
tumors and liver tumors were the two end points.
A serial sacrifice design was employed. One group of
animals was on continuous exposure. For a secondgroup,
exposure ceased atpredetermined timesbefore sacrifice.
For all animals other than controls, exposure started at
birth; this eliminates one interesting variable from the
multistage model and reduces power in testing it.
Like other authors (12-13), we could notfit a multistage
model to the bladder cancer data. With liver cancer, the
model does fit a substantial part ofthe data, but then ex-
trapolations to the rest ofthe data set are not so success-
ful (27-31).
Peto Mice. The object of the beautiful experiment
described in Peto et al. (10) was to demonstrate that du-
ration rather than aging per se affects cancer risk. The
carcinogenic agent was benzpyrene painted on the skin.
The end point was malignant skin cancer. No control
group was provided, probably because the tumor has no
spontaneous incidence. Only one dose level was used,
limitingthepowerofstatistical tests. Paintingwas started
at 10, 25, 40, or 55 weeks of age. The point is that inci-
dence depends on duration ofexposure not age at start,
but Peto et al. do not really test the fit ofthe multistage
model to the data. Further arguments are givenby Peto,
Parish, andGray (32). Peto et al. report a strong, ifpara-
doxical, effect forage at start ofdosingwith NDEA(33);
also see Drew et al. on vinyl chloride (34), orAmes more
generally (35).
Collapsing the data seemed advisable to improve the
asymptotics and the power(6). We triedmodels with five
throughnine stages, thefirstandnext-to-lastbeingpoten-
tially sensitive. The best model had six stages, and X2 =
67 on 37 degrees offreedom, p = 2/1000.
As will be argued, even setting aside the question of
whether the model fits the data, the experiment cannot
really separate age from duration within the multistage
framework, because the stages in the model are statisti-
cal constructs, with no biological definition.
Simulation Studies
Inthe present context, simulation studies(6) showthat
maximum likelihood estimates andX2 testsperform quite
well although difficulties are created by sparse cells and
positivity constraints. Parameter estimates are far from
normally distributed, due to end point effects so Wald's
analogofthe t-test doesnotperformwell. Inthepresent
context, the X2 statistic is preferred to the likelihood ra-
tio statistic. Differencing the X2's to test constraints is
reasonably effective and agrees with results from the
score test; ingeneral, thelattermaybe preferred. Refer-
ences onthetheoryare Lehmann(36,37), Kalbfleisch and
Prentice on failure-time data (38), and Rao on the score
test (39).
Discussion
Withlungcancer, thereis substantial conflict amongthe
various data sets as to the sensitivity ofthe stages; pro-
jected risks for nonsmokers or ex-smokers are inconsis-
tent with observations. Likewise, in the mega-mouse
study, there is some difficulty in extrapolating from one
part ofthe data set to another (high risk to low risk, or
continuous exposure to ceased exposure); bladder cancer
does not fit at all. Such discrepancies make it less likely
that the model is correctly describingthe mechanisms of
carcinogenesis and tend to undercut the reliability ofthe
model in risk assessment. However, the findings are con-
sistent with the view of-the model as a family of curves
that more or less fit various data sets without necessar-
ily capturing the underlying biological reality.
Ofcourse, testing the multistage model on data raises
questions not only about the model but also about the
data. The model couldbe wrong, or the data, orboth. For
example, take the British doctors. The modelpredicts too
many cases among the heavy smokers and the older co-
hort members. This may reflect afailure ofthe model or
flaws in the data. Thus, Doll and Peto (9) argue that the
heavy smokers have overreported their smokinghabit, or
in the alternative that such smokersinhale less. Forolder
persons, diagnostics maybepoorer orthesepersons may
be more cancer-proof; the latter idea goes back to Pearl
(40).
Otherpossible explanations forlackoffit in such cases
include individual differences in model parameters, per-
haps due to genetic variation; dependence of competing
risks; relatively longer times from malignancy to death
for younger cohort members; and underreporting ofdose
bylight smokers. Changes inthe composition ofcigarettes
overtime are anothercomplication. Later age at start of
smokingamongoldercohortmembers should also be con-
sidered, as in Stevens and Moolgavkar(41); however, this
does notfit so well withthe veterans orACS data, where
controllingfor age at start ofsmokingmakeslittle impact
on the deficit in events at old age.
Up to apoint,judgment calls inflttingmaybe in order,
especially ifthere is some corroborating evidence. On the
other hand the data can almostalways be censored orad-
justed so a multistage model fits, or the model can be
tuned alittle tofittheremaining data. Moreover, factors
that affect those portions of the data where the model
seems not to fit may also affect the region where the fit
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seems good, so the fit can bejust as much an artifact as
the lack of fit. Ultimately, censoring the data or tuning
the model to the datablunt the force ofempirical conclu-
sions.
Some readers may find our approach of fitting the
model and testing by chi-squared or making extrapola-
tions and checking them too mechanical. The model does
provide a rich and loosely defined class ofpolynomials for
describing data, a heuristic for suggesting hypotheses
about biological mechanisms, a demonstration that the
powerlaw for incidence rates is compatible with a series
of discrete cellular changes, and a source of beautiful
mathematical puzzles. Ifthose were the only virtues at-
tributed to the model, our critical approach might be out
ofline. However, quite literal and dogmatic inferences are
sometimes drawn from the model, particularly in the field
of risk assessment. A strict approach to testing such a
model may be in order.
Otherreaders maybe concerned, andrightly so, about
the sample size issue: With a large enough sample, any
model may be rejected. Our results do suggest that the
multistage model will be accepted when the number of
events is relatively small and rejected when the number
is relatively large. On the other hand, one conventional ar-
gument forthe statistical version ofthe multistage model
is that it fits the data. While failure to fit may not prove
the model to be wrong, it cannot show the model to be
right. Patterns oferrorin thefit, discrepancies amongco-
horts, and systematic errors in prediction seem relevant
in assessing the merits ofthe conventional evidence for
the model.
Our view is that on the whole, fitting the multistage
model to cancerincidence datain humans orinbioassays
does not seem likely to yield much new understanding
about the mechanisms of cancer, unless the modeling
results can be rigorously checked against observable
phenomena, in the lab and in human populations. Relia-
ble procedures for estimating cancer risks seem to be a
long way off, barring some breakthrough in the biologi-
cal understanding. Some of the alternative models are
worth exploring (18).
Cook, Doll, and Fellingham show that while many can-
cerincidence data sets fit themodel, many others do not,
andproblems withadjustments are discussed(8). Doll and
Peto felt thatthe multistage model was apromising ave-
nue to explore "even if current knowledge is too sparse
for such models to be tested critically" (9). Peto reviews
the biological evidence (42); Doll and Peto cannot be
described as enthusiastic about dose-response models in
risk assessment (43). Also see Wald and Doll (44). Ar-
mitage says that "Until and unless we obtain direct evi-
dence about the presence and nature of intermediate
stages, any statistical theory is likely to remain largely
unfalsiflable, particularly if it is allowed to be modified
withtheflexibility towhich we have become accustomed"
(45).
For recent somewhat critical reviews, see Freedman
and Zeisel (16) and Kaldor and Day (17). On the positive
side see Lave (46), Vouk et al. (47), and Zeise et al. (48).
Proponents of risk assessment have suggested reading
the Foodand DrugAdministration reporton saccharin as
an example ofwhat canbe done (49). Forcritical comment
on those risk assessments, see the National Academy of
Sciences report on saccharin (50).
Detailed Results for Lung Cancer
Introduction
This section will report details ofthe modeling results
on the three main lung cancer data sets: the British doc-
tors, the Dorn veterans, and the ACS volunteers. Lung
cancer data are usuallymodeledwith one early stage and
one late stage allowed to be sensitive; the first and next-
to-last are the conventional choices. Dose will be meas-
ured in cigarettes per day; To denotes the age at start of
smoking; for ex-smokers, T, denotes the age at quitting.
Consider the hazard rate h(t) given by a multistage
model, with the following interpretation: A person who
survivesto age thas chance h(t)dtofcontractinglungcan-
cer in the time interval(t,t + dt). The fornulasforh(t) are
derived inWhittemore and Keller(4); Kalbfleisch et al. (5);
and Freedman and Navidi (6); the relevant ones are pre-
sented here. Equations 1-3 describes an n-stage model,
with the 1st and n-lst potentially sensitive. Nonsmokers
are covered by Equation 1, current smokers by Equation
2, and ex-smokers by Equation 3. The dose rate is as-
sumed constant over the period of smoking:
Atn-l [1]
Atn-i + Bdose(tn-I
+ Cdose(t - To)'-'
+ Ddose2(t - TO)
Atn'- + Bdose(T1 '-I
+ Cdose[(t-To)'1 - (t -TI)n-1]
+ Ddose2(T1 - To)n-I
[2]
[3]
In Equations 4-6, stages 1 and n are potentially sensi-
tive; again, Equation 4 is for nonsmokers, Equation 5 is
for current smokers and Equation 6forex-smokers. Equa-
tion 4 makes sense for n > 3; Equation 5, for n > 2.
Atn-[ [4]
Atn-i + Bdose tn-
+ Cdose (t - TO)'- + Ddose2 (t -To) - [5]
+ Cdose [(t -TO)'' -(t - T)n-1] [6]
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The number ofevents in each cell ofthe basic cross tab
(Table 2 for the British doctors) is taken to be Poisson, and
independent from cell to cell. The expected number in a
cell is the hazard rate times the number of person years.
The latter is treated as constant in the modeling, even
though it is slightly random. This last approximation
seems to be quite good in the present context (6); for
asymptotic theory, see Aalen (51) and Jacobsen (52). The
independence of competing risks is needed to compute
the expected value.
After suitable aggregation ofthe data, the coefficients
in models Equations 1-3 and Equations 4-6 can be esti-
mated by maximum likelihood, and then the goodness-of-
fit can be assessed by the X2 statistic:
x2 = E (obs - exp)2/exp [71
We also considered using the Neyman-Pearson likelihood
ratio statistic (or Wilks statistic):
Irs(X) = 2{supOEG log L(XIE) [8]
- SUPEO N logL(XIE)})
Here, L is the likelihood function, X the data, and 0 the
parameter vector, for example, the 24 Poisson means for
the British doctors (Table 3). The first sup is overthe set
G ofall parametervectors, namely, the saturated Poisson
model. The second sup is over N, the setof e's correspond-
ing to multistage models. Simulation results (6) suggest
that X2 has close to its asymptotic chi-squared distribu-
tion, while lrs is a little too big.
The coefficients A,B,C,D in Equations 1-3 and 4-6 must
be nonnegative, and satisfy the constraint AD = BC. The
coefficient A reflects background rates only; B includes
the sensitivity ofthe late stage; C, the sensitivity ofthe
early stage; D, the sensitivity ofboth stages. IfB = D =
0, then the late stage is insensitive; if C = D
= 0, the early stage is insensitive (6).
If stages 1 and n are sensitive, ex-smokers show an
abrupt drop in predictedrisk: As tincreases fromjustbe-
low T, tojust above T1, the hazard ratejumps down, be-
cause terms involving the sensitivity of that stage drop
out (compare Eq. 3 with Eq. 6 at t = TI). In other words,
the hazard reverts to that of an n-stage model with only
the first stage sensitive. This discontinuity is a well-
knownfeature oflast-stage sensitivity andis an argument
against suchmodels. The British doctors' data are toothin
to reject implausible models. Equally, these data cannot
provide strong evidence in favor ofpreferred models.
British Doctors
lables 4 and 5 show the empirical results for the non-
smokers and current smokers amongthe British doctors,
Table 4. Modeling results for the British doctors.a
n A B C D x2 Comment
3 0.21 0.0055 0.50 0.013 101 Does not fit
0.09 0.0056 0.18
4 0.41 0.011 1.46 0.038 43 Does not fit,
0.17 0.011 0.49 p = 3/1000
5 0.80 0.035 2.76 0.12 21 Fits: 1st and 4th stages
0.31 0.033 1.25 sensitive
5 0.77 b 5.78 b 27 Fits, but X1 = 5.5C;
0.31 b 0.43 1st stage only sensitive
6 1.50 0.45 1.16 0.35 20 Fits: 1st and 5th stages
0.54 0.22 0.88 sensitive
6 1.32 1.47 b b 42 Does not fit; 5th stage
0.53 0.11 b only sensitive
7 2.16 1.44 0.73 0.49 23 Fits; 1st and 6th stages
0.85 0.33 0.51 sensitive
2
7 2.07 2.36 b b 30 Fits, but Xi = 7.5;
0.83 0.18 b 6th stage only sensitive
8 3.13 3.21 0.35 0.36 30 Fits; 1st and 7th stages
1.28 0.52 0.42 sensitive
8 3.11 3.69 b b 31 Fits; 7th stage only
1.27 0.28 b sensitive
9 4.52 5.61 0.00 0.00 43 Does not fit
1.86 0.79 0.56
10 6.39 8.33 0.00 0.00 67 Does not fit
2.66 1.17 1.08
aCurrent smokers ofcigarettes only at constant dose and nonsmokers. Dose is in cigarettes per day. There are n stages; 1 and n-1 are allowed to
be sensitive. SEs are shown below estimates. Estimates are constrained to be nonnegative. Coefficients estimated as 0 are reported as 0.00. The
estimates and SEs should be dividedby 102n+I'. The age range is 25-84, heavy smokers included. There are 21 degrees offreedom for X2. A variety
of models fit.
bEstimate has been forced to 0.
CX2 is the difference between the X2s for the restricted and unrestricted models.
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Table 5. Modeling results for the British doctors.a
n A B C D x2 Comment
3 0.20 0.0046 0.53 0.012 102 Does not fit
0.09 0.0048 0.18
4 0.40 0.0010 1.40 0.036 43 Does not fit
0.17 0.0010 0.49
5 0.80 0.034 2.78 0.12 22 Fits; 1st and 5th stages
0.31 0.032 1.24 sensitive
5 0.77 b 5.78 b 27 Fits, but X1 = 5.5C;
0.31 b 0.43 1st stage only sensitive
6 1.51 0.44 1.23 0.35 20 Fits; 1st and 6th stages
0.54 0.21 0.92 sensitive
6 1.32 1.47 b b 42 Does not fit; 6th stage
0.53 0.11 b only sensitive
7 2.16 1.42 0.75 0.49 23 Fits; 1st and 7th stages
0.85 0.33 0.52 sensitive
7 2.07 2.36 b b 31 Fits, but x2 = 7.5;
0.84 0.18 b 7th stage only sensitive
8 3.13 3.20 0.36 0.37 30 Fits; 1st and 8th stages
1.28 0.52 0.42 sensitive
8 3.11 3.68 b b 31 Fits; 7th stage only
1.27 0.28 b sensitive
9 4.52 5.61 0.00 0.00 43 Does not fit
1.86 0.79 0.56
10 6.39 8.33 0.00 0.00 67 Does not fit
2.66 1.17 1.08
aCurrent smokers ofcigarettes only at constant dose and nonsmokers. Dose is in cigarettes per day. There are n stages; 1 and n are allowed to
be sensitive. SEs are shown below estimates. Estimates are constrained to be nonnegative. Coefficients estimated as 0 are reported as 0.00. The
estimates and SEs shouldbe dividedby 102,1 +I. The age range is 25-84, heavy smokers included. There are 21 degrees offreedom forX2. A variety
ofmodels fit.
bEstimate has been forced to 0.
Cx2 is the difference between the X2's for the restricted and unrestricted models.
with Equations 1 and 2 and Equations 4 and 5, respec-
tively; heavy smokers are included in bothtables, andthe
age range is 25 to 84 years.
The tables are remarkably similar because the only dif-
ference between Equations 2 and 5 is in the second term.
In that term, t`1 dwarfsTo`~ when t is upwards of50 or
so, where all the lung cancer cases are. So the two for-
mulas are virtually identical for current smokers. In
either case, avariety ofmodelsfitthe data. There areonly
about 200 events, and that is not enough to pin things
down.
Standard errors shown in the tables are computedfrom
the Fisherinformation matrix, and the usual asymptotics
do not apply when estimated coefficients are close to 0.
There could be a similar issue for the chi-squared test.
Searching over n creates another problem. However,
simulation studies(6) suggest that in the present context,
theseproblems are not serious, except the distribution of
some ofthe estimates isquiteasymmetric andlong-tailed.
That maybe the reason why in the six-stare model, con-
straining C to 0makes abig difference in X , althoughthe
estimate is only 1.3 times the standard error. The Wald
t-test is not appropriate here (6,53,54).
Doll and Peto fit their model on the age range 40 to 79
anddoserange 0to 40. As afinal test, wefitthe six-stage
model on this portion ofthe data (X2 = 12 on 20 degrees
offreedom) and use it topredictthe restofthe data(ages
25-84 and any dose). The data beyond age 85 are elimi-
natedin viewofthe deficitin eventsamongthe oldestper-
sons; the data on ages 20 to 24 are eliminated too, since
age at start of smoking was imputed as 22.5.
The predictions are systematically too high. In total,
there are 32 events predicted and 12 observed; by simu-
lation, p = 3/1000 (6). Even for those aged 80 to 84 and
smoking 40 cigarettes a day or less the predicted is too
high: 16, with 6 observed. The predicted number is also
too high among those aged 39 or less and smoking 40
cigarettes a day orless, but that couldeasily be a matter
of chance.
The model fitted by Doll and Peto to the non-smokers
and current smokers is not exactly a multistage model:
(a + b dose)2 (t - 22.5)n-l [8a]
This fits into the multistage framework only by having
smokers and nonsmokers alike start on the progression
tomalignancy at age22.5; compareEquations 11 and 12.
However, for the British doctors, the A-term inEquation
2 is rathersmall, and the B-term can more or less be ap-
proximated by a multiple of(t-22.5)n-1.
Doll and Peto take To = 22.5; they report an average
age of19 at startofsmokingand add3.5 years forlatency.
We redid the tables with To = 19; the fit was worse for
n = 3,4,5, but very similar for larger n.
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Dorn Veterans
The modeling results for the Dorn veterans are
reported in Table 6. The best model for the current
smokers has six stages, but does not fit (p = 5/100,000).
In this model, only the late stage is sensitive. (By compar-
ison, the six-stage model for the doctors has both stages
comingin.)With only the late stage sensitive, the model
predicts almost no response to age at start of smoking;
those who start early and those who start late will have
nearly the same risks. In reality, of course, starting early
causes a huge increase in risk (55).
Next, Table 7 shows the observeds and person-years in
the veterans data. Table 8 shows the residuals from the
six-stage model in Table 6. On the whole, the residuals
seem to be negative around the edges of the table and
positive in the middle. For persons aged 75 or more, some
ofthe discrepancies maybepractically significant as well
as statistically significant.
ACS Volunteers
Table 9 gives results for the ACS men. The best-fitting
model has six stages (p = 1%); the effect ofthe late stage
is insignificant. When used to predict the risk for non-
smokers, this model predicts 500 + 60, with 99 observed,
p < 1/1,000,000. (This sort ofcross-validation has two ad-
vantages: to some extent, it corrects for data snooping;
and to some extent, itpicks up heterogeneity in the data.)
The data for the ACS men are shown in Table 10. The
residuals in Table 11 resemble the veterans data in pat-
tern ofsigns. For all three data sets (the doctors, the vet-
erans, and the ACS men), the best-fitting models over-
predict risk around the edges. Of course, the model could
be right and this pattern could be artifactual.
Many models fit the data for ACS female current
smokers including those with no background rate (Table
12): extrapolating on that basis from smokers to non-
smokers shows the latter will not get lung cancer. Such
modelswould notbe makinggoodpredictions, as ACSfe-
male nonsmokers get lung cancer at fairly high rates.
Even the best-fitting model predicts 100 + 150 events,
with 229 observed. The trouble is that the ACS women
smokers only have 164 events. As for the British doctors
there are not enough events to pin things down.
Ex-Smokers
Modelsfitted to current smokers do notpredictwellfor
ex-smokers, as noted above. The discussion is continued
inthis section. There seems tobegeneral agreementthat
when smokers quit, their excess riskfreezes (22,42,55,56).
Absolute risk (background + excess) must therefore in-
crease as a function oftime since quitting. However, the
data show a drop in risk on cessation of smoking.
To illustrate the predictions, Table 13 computes risks
from three multistage models: the ones that best fit the
nonsmokers or current smokers among the British doc-
tors, the American veterans, and the ACS men(six stages
with first and fifth allowed to be sensitive; for the ACS
men, the model is fitted to current smokers only). The
risks are computed for three groups of men: NON, the
nonsmokers; CS, the current smokers with age at start
22.5 and constant dose of a pack a day; EX, the ex-
smokers, who started smokinglike CS butquit at age 50.
Tb compute the table, the models given by Equations
1 and2 are fitted to the nonsmokers and current smokers
to estimate the coefficients A,B,C,D. Then Equation 1 is
used to compute the riskfornonsmokers, 2 is usedforthe
current smokers, and 3 is used to project the risk for ex-
smokers.
One problem is that the projections ofthe three models
are quite discrepant. For an extreme example, take the
Table 6. Modeling results for the Dorn veterans.a
n A B C D x2 Comment
3 0.56 0.00 0.58 0.00 130 Does not fit
0.042 0.0016 0.05
4 0.83 0.00 1.27 0.00 69 Does not fit
0.06 0.002 0.11
5 1.24 0.00 2.66 0.00 58 Does not fit
0.09 0.003 0.23
6 1.75 1.01 0.00 0.00 50 Best fit, p = 5/100,000
0.13 0.072 0.02 5th stage only sensitive
7 2.51 1.50 0.00 0.00 70 Does not fit
0.19 0.11 0.04
8 3.55 2.21 0.00 0.00 118 Does not fit
0.27 0.16 0.07
9 4.99 3.21 0.00 0.00 196 Does not fit
0.38 0.23 0.14
10 6.96 4.64 0.00 0.00 309 Does not fit
0.53 0.32 0.24
aCurrent smokers ofcigarettes only and nonsmokers. Dose is in cigarettes per day. There are n stages; 1 and n-1 are allowed to be sensitive. SEs
are shown below the estimates. Estimates are constrained to be nonnegative. Coefficients estimated as 0 are reported as 0.00. The estimates and
SEs should be divided by 102n+ '. There are 17 degrees of freedom for X2. No model fits.
176MULTISTAGE MODELS FOR CARCINOGENESIS
Table 7. The Dorn veterans: Events/person-years, current smokers ofcigarettes only and nonsmokers.
Dose, cigarettes per day
Age 0 1-9 10-20 21-39 40+
Below 55 2/84,401 0/9,366 19/72,002 23/46,532 3/4,728
55-64 25/212,448 18/16,417 111/67,593 129/48,307 37/9,860
65-74 119/363,152 25/27,460 294/94,061 258/53,278 72/10,072
75 or more 27/75,499 2/5,164 63/13,959 31/5,595 8/906
Table 8. Residuals for the Dorn veterans, from the best-fitting model in Table 6.a
Residuals O/E
Dose, cigarettes per day
Age 0 1-9 10-20 21-39 40+
Below 55 -1 -1 -3 -5 -2
55-64 -6 9 19 5 -4
65-74 16 -5 44 -8 -9
75 or more -12 -8 -4 -19 -5
aThe model overpredicts around the edges and underpredicts in the middle, for current smokers of cigarettes only and nonsmokers.
Table 9. Results for the ACS male current smokers.a
n A B C D x2 Comment
3 1.58 0.00 0.25 0.00 315 Does not fit
0.31 0.008 0.07
4 2.54 0.00 0.64 0.00 127 Does not fit
0.48 0.01 0.16
5 4.51 0.00 1.45 0.00 38 Does not fit
0.75 0.02 0.35
6 9.02 0.028 2.52 0.0077 28 p = 1%; 1st and 5th stages
1.07 0.047 0.73 sensitive
6 8.59 b 3.00 b 28 p = 1%; 1st stage only
1.01 b 0.23 sensitive
7 11.15 0.99 0.00 0.00 30 p = 0.5 of 1%;
1.82 0.16 0.22 6th stage only sensitive
8 14.91 1.70 0.00 0.00 68 Does not fit
2.72 0.23 0.33
9 19.09 2.84 0.00 0.00 158 Does not fit
4.00 0.34 0.51
10 23.29 4.63 0.00 0.00 305 Does not fit
5.77 0.50 0.72
aNonsmokers are excluded. There are n stages; 1 and n-1 are allowed to be sensitive. Dose is in cigarettes perday. SEs are shownbelowthe esti-
mates. Estimates are constrained to be nonnegative. Coefficients estimated as 0 are reported as 0.00. The estimates and SEs should be dividedby
102n+ '. There are 13 degrees of freedom for X2. The six-stage model barely fits.
bEstimate has been forced to 0.
Table 10. ACS men: Events/person-years, current smokers only.
Dose, cigarettes per day
Agea 1-9 10-19 20-39 40+
Below 55 24/62,581 62/127,178 355/445,541 98/96,678
55-64 38/32,915 116/58,558 403/147,636 102/25,885
65-74 23/13,249 76/19,981 189/32,233 24/3,516
75 or more 6/2,211 11/2,333 14/2,375 1/178
aAge is at the beginning ofthe study, in 1959.
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saving in relative risk at age 75 from quitting at age 50,
namely, 1-(EX/CS). From the model fitted to the doctors
or the veterans, this is estimated as 80%. But from the
ACS men, the estimate is only 7%.
The main point is that the predictions seem to be
qualitatively wrong. The predicted excess risk (EX -
NON) increases steadily for the doctors and the ACS
men, rather than freezing: the reason is that in the model,
the first stage is sensitive, so the C-term in Equation 3
is positive and increasing. The excess risk is predicted as
constant for the veteran ex-smokers because only the late
stage is sensitive, so the excess risk is the B-term in
Equation 3. The predicted absolute risk for ex-smokers
increases rapidly with time since quit for all threemodels,
as in Table 13.
Table 14 shows the observed and expected number of
lung cancer cases among the veteran ex-smokers. The ex-
Tlble 11. Residuals fortheACSmen from the six-stage model with
first and fifth stages sensitive in Table 9.a
Residuals O/E
Dose, cigarettes per day
Age 1-9 10-19 20-39 40+
Below 55 -1 -6 16 -12
55-64 -0 17 29 5
65-74 -10 1 -1 -8
75 or more -5 -7 -16 -3
aThe model overpredicts around the edges and underpredicts in the
middle for current smokers.
pected are from the six-stage model ofTable 6: Equations
1 and 2 are fitted to thenonsmokers and current smokers,
then Equation 3 is used to predict the risk for the ex-
smokers. The model underpredicts in the early years and
then overpredicts. (Of course, part of the reason for ex-
Table 12. Results for the ACS female current smokersa
n A B C D x2 Comment
3 0.14 0.032 0.0027 0.00062 16 Fits
0.13 0.025 0.0095
3 0.098 b 0.10 b 15 Fits; 1st stage
0.086 b 0.014 only sensitivec
3 b b 0.11 b 17 Fits; 1st stage only and
b b 0.0089 . no background
4 0.24 0.059 0.0064 0.0016 8 Fits; 1st and 3rd stage
0.24 0.039 0.024 sensitive
4 0.19 b 0.30 b 8 Fits; 1st stage only
0.16 b 0.043 sensitive
4 b b 0.35 b 10 Fits; 1st stage only and
b b 0.027 no background
5 0.34 0.12 0.0079 0.0027 6 Fits; 1st and 4th
0.43 0.062 0.040 stages sensitive
5 0.26 0.13 b b 6 Fits; 4th stage only
0.30 0.019 b sensitive
5 b 0.15 b b 7 Fits; 4th stage only and
b 0.011 b no background
6 0.43 0.24 0.0018 0.00097 8 Fits; 1st and 5th
0.75 0.10 0.048 stages sensitive
6 0.41 0.24 b b 8 Fits; 5th stage only
0.53 0.033 b sensitive
6 b 0.26 b b 9 Fits; 5th stage only and
b 0.020 b no background
7 0.61 0.43 0.00 0.00 15 Fits; 6th stage only
1.27 0.17 0.09 sensitive
7 b 0.46 b b 15 Fits; 6th stage only and
b 0.036 b no background
8 0.84 0.76 0.00 0.00 25 p = 2%
2.11 0.27 0.17
9 1.03 1.31 0.00 0.00 40 Does not fit
3.41 0.43 0.28
10 1.00 2.22 0.00 0.00 60 Does not fit
5.37 0.67 0.36
aNonsmokers are excluded. There are n stages; 1 andn-i are allowed to be sensitive. Dose is in cigarettes per day. SEs are shown below the esti-
mates. Estimates are constrained to be nonnegative. Coefficients estimated as 0 are reported as 0.00. The estimates and SEs should be divided by
102n+ '. There are 13 degrees offreedom for X. A variety ofmodels fit, including quite implausible ones. In these data, either B or C and A can be
constrained to 0; not all possibilities are reported.
bEstimate has been forced to 0.
cThe fit is by maximum likelihood, not minimum X2; occasionally, constraints will improve the X2.
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TIble 13. Predicted lung cancer deaths per 100,000 person years for nonsmokers, current smokers, and ex-smokers.a
Doctors Veterans ACS men
Age NON CS EX NON CS EX NON CS EX
50 5 58 58 6 67 67 28 38 38
55 8 112 66 9 109 71 45 68 66
60 12 202 78 14 170 76 70 114 110
65 17 348 99 20 254 82 105 185 176
70 25 571 130 30 368 92 152 290 274
75 36 900 175 42 520 104 214 441 412
aAge at start ofsmoking is 22.5 years, and dose is a pack per day; the ex-smokers quit at age 50. The risks are predicted from multistage models
fitted separately to three cohorts. The models are inconsistent with each other, and the results are incompatible with the freezing ofexcess risk on
quitting. Non, nonsmokers; CS, current smokers; Ex, ex-smokers.
Table 14. Veterans ex-smokers: Observed lung cancer deaths and numbers expected from the six-stage model in Table 6.a
Years since Person- Observed per
quitb years Observed 100,000 person-years Expected O/E
0-4 15,693 26 166 20.4 1.27
5-9 33,633 45 134 41.1 1.09
10-14 41,786 52 124 46.9 1.11
15-19 35,008 25 71 33.1 0.76
20-24 27,878 11 39 17.4 0.63
25-29 21,844 6 27 10.8 0.55
30-34 13,426 4 30 6.6 0.61
35+ 4,212 0 0 2.1 0.00
aThe observed number of cases per 100,000 person years declines steadily, and so does the ratio of observed to expected. Persons who quit due
to doctor's orders are excluded from the data.
bYears since quitatthebeginningofthe study isgiven by5-yearintervals; this is replaced by atruncated midpoint in the calculation. Forexample,
a person who quit 5-9 years before 1954 is assumed to have quit in 1947.
cess events in Table 14 maybe that sickpeople quit smok-
ing.) Only the late stage in the model is sensitive; mak-
ing the last stage sensitive instead of the next-to-last
would barely affect Table 6; it would make the under-
prediction problem in Table 14 even worse but would par-
tially correct the overprediction.
Asfar as we cantell, the excess riskinfactdeclineswith
years since quitting rather than freezing; even the abso-
lute risk (background + excess) declines, quite contrary
to the predictions ofthemodel. Table 14 showsthe decline
for the veterans. These data are sparse, so cross-
tabulation to control survivorbias does not seem advisa-
ble; however, controlling for the term dose x (Tl-1 -
Tonl-) in Equation 3, as an indicator of risk, does not
change the picture very much. Nor does indirect stan-
dardization on the risk at time of quitting. The spike in
risk at the time of quitting, however, is noticeable.
For the ACS men too, Table 15 shows that the absolute
risk(events per 100,000 personyears) declines steadily as
afunction oftime since quitting. The first line in Table 15
maybe an artifact(sickpeople quit smoking). The lastline
may be low due to the missing events for older persons.
Evenbetween lines 2 and3, there maybe a survivorbias:
The men most at risk die early. However, controlling for
age at quitting and dose (by cross-tabulation) makes lit-
tle difference, so survivor bias does not seem to be a big
problem.
The absolute risk does seem to drop with time since
quitting for the veterans and ACS males; the rapid in-
creasepredicted by themodel simplyis notthere. Ib state
thepoint more sharply, constant excess risk isincompat-
ible with the sensitivity ofthe first stage, needed so that
age at start influences the response; decreasing excess
risk is incompatible with any of the models fitted here.
(The phenomenon canbe incorporatedby havingrandom
parameters or alongandvariablelatencyperiodbetween
malignancy and death.)
For the British doctors, data on ex-smokers are not
available. However, the risk for ex-smokers seems to be
less than their risk at time ofquitting, until 20 years af-
terquitting; the numbers are small, but in aggregate, the
observed numberofevents forthe ex-smokers is less than
predicted from the risk at time of quitting (57). On the
whole, our results are consistent with this finding [for
other data and reviews, see (58-61)].
For a literature review on lung cancer, see the IARC
monograph (55). With bladder cancer, the risk is consid-
ered to drop when exposure ceases (55). For experimen-
tal results on regression oflesions when carcinogenic in-
Table 15. Observed absolute risk for ACS male ex-smokers (number
oflung cancer deaths per 100,000 person years) by years since quit
smoking.
Years since Person- Number Rate per
quita years of events 100,000 person-years"
< 1 42,053 69 164
1-4 97,469 111 114
5-9 201,655 108 54
10+ 66,566 6 9
aYears since quit is at thebeginning of the study, in 1959.
'These are crude rates; standardization does notchange thepattern
(54).
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sult stops, see McKenzie and Rous (62); Hennings et al.
(63); and Farberand Sarma(64); inthe other direction, see
Littlefield et al. (28). There is further discussion of ex-
smokers in Freedman and Navidi (65) and Gaffney and
Altshuler (66). Gaffney and Altshuler focus on the Brit-
ish doctors. They find declining excess risk after cessa-
tion of smoking, and note the inconsistency with the
Armitage-Doll model. They present an alternative model.
The tensionbetween modelsforcontinuing smokers and
ex-smokers seems to be well known. The resolution at-
tempted in Brown and Chu (22)is not satisfying. The mul-
tistage model in that paperisfitted not to databut to out-
put from logistic regressions, which are themselves
inconsistent with the multistage model; the parameters
ofthe fitted multistage model are allowed to depend on
dose; age and duration of smoking are treated as extra
parameters, constant across subjects, and estimated, even
though the data are available.
Some Technical Issues
Latency
After acell(orclusterofcells)becomes malignant, some
period oftime must elapse until the cancerbecomes clin-
ically detectable; and another period oftime until death
ensues. These periods oftime are the latencies. The first
waitingtime is not empirically observable, almostby def-
inition; so there is little direct evidence about its distri-
bution: indirect evidence suggests this time may be ap-
preciable (67,68). (Of course, otherevidence might suggest
this time is short.) The second waiting time has been
studied for many human cancers; for lung cancer, it may
be on the order of 18 months.
Latency complicates the modeling problem even fur-
ther. Some authors treat latency as constant across sub-
jects, to be estimated statistically along with the other
parameters in the multistage model; others treat the
latency as following some textbook distribution (like the
Weibull), whose parameters are then estimated. Such as-
sumptions are hard to defend empirically.
Unless noted otherwise, we cut the knot by setting
latency to zero. This has the advantage ofsimplicity, but
cannot be taken too literally. The problem is serious, be-
cause in the end the data are on times to a clinically de-
tectable end point. If a large part ofthe distribution for
that time is left unspecifled, the model is poorly defined.
As apractical matter, allowingpositive latency reduces
the number ofestimated stages, by increasingthe rate of
change ofthe fitted hazard function at the relevant time
period.
Independence of Competing Risks
Let T be the time to failure for the whole tissue in the
multistage model, namely, the time forthe first target cell
to complete its progression through the n stages of the
process. Then the conditional distribution of Tgiven T > t,
is assumed equal to the distribution ofTgiven survival on
test to time t. (In the latter event, we condition not only
that T > t, butthat all risks mature aftertime t.) The as-
sumption ofequality is a version ofindependence of com-
petingrisks, which allows the model to be used even when
the data on waiting times are censored by death from
other causes; and in the case ofhuman subjects, by with-
drawal from the study, data selection by the investigators,
etc.
This assumption may not be verifiable from the data
(69), and we can see only two possible defenses: a) It has
been used since the time of Bernoulli; b) it is at present
impossible to do risk modeling any other way.
Pooling
For estimation and testing, it is necessary to arrive at
some definite aggregation ofthe data, which in our exam-
ples is usually presented in the form of a two- or three-
dimensional cross-tab. It will be advantageous to pool
cells, eliminating the sparse ones. This improves power
(up to a point) and makes the null distribution of the X2
statistic closer to the asymptotic limit; for some empiri-
cal evidence, see Freedman and Navidi (6).
make the asymptotics ofthe X2 test go through, the
same aggregation must be used for both estimation and
testing. For the lung cancer data sets, the aggregation
was suggested by the age x dose table in Frome and
Checkoway (70). The same four age groups were used for
all cohorts: a) 54 or less; b) 55 to 64; c) 65 to 74; and d) 75
or more.
For the British doctors, we chose six dose groups
(cigarettes per day): a)0; b) 1 to 9; c) 10 to 19; d) 20 to 29;
e) 30 to 40; and f) 41 or more. For the veterans and the
ACS volunteers, there were five dose groups as in the raw
data: a) 0; b) 1 to 9; c) 10 to 20; d) 21 to 39; and e) 40 or
more. (For the volunteers, group c was 10-19 and group
d was 20-39. Occasional smokers in the veterans cohort
were excluded.)
Forthe British doctors, there are 4 x 6 = 24 cells in the
aggregated cross-tab (Table 3), 4 parameters A,B,C,D, and
1 constraint (AD = BC) so the X 's have 24 - 4 + 1 = 21
degrees offreedom. The veterans have 4 cells fewer and
17 degrees of freedom in the X2's. The ACS data has no
nonsmokers and 13 degrees of freedom.
The next object is to explain how aggregate cross-tabs
are derivedfrom the raw data, with the current smokers
in the British doctors as afirst example. The original data
are given in Table 2 and the aggregation in Table 3. Tb il-
lustrate the arithmetic, the datafor ages 55 to 64 and dose
30 to 40 are reproduced from Table 2, as Table 16.
In Table 3, there is a cell corresponding to ages 55 to
64 and dose 30 to 40. The number ofevents in that cell is
obtained by adding the numbers of events in the basic
Table 16.
Dose, cigarettes/day
Age, years 30-34 35-40
55-59 6/1923 4/1063
60-64 11/1362 7/826
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cells above: 6 + 4 + 11 + 7 = 28, and likewise for the
person-years.
The second example is the veterans' data. How do we
get from the raw data on the tape to the aggregate data
in Table 7? The raw data can be used to make a three-
dimensional cross-tab ofbasic cells:
age x age at start of smoking x dose
For nonsmokers, there is only one dimension ofinterest:
age. For ex-smokers, there are four dimensions: age, age
at start ofsmoking, age atquitting, dose. The tapereports
year of birth and death; age at start or quit is only
reported by 5-year groups.
Forinstance, one basic cellinthe cross-tab corresponds
to current age 55 to 59, age at start 20 to 24, and smokes
10to20 cigarettes per day. Until death, subjects may con-
tribute person years to each basic cell in the three-
dimensional cross-tab and an event if they die of lung
cancer.
Each age x dosegroup inthe aggregate cross-tab isthe
result ofpooling over a set ofbasic cells. Forexample, con-
sider thefollowing cell in the aggregate cross-tab: current
age 55 to 64, smoking 10 to 20 cigarettes perday. Person
years, observeds and expecteds forthat cell are obtained
byaddingup the numbersforthe basic cells inthe three-
dimensional cross-tab, corresponding to current age 55 to
59 or 60 to 64; age at start ofsmoking 5 to 9, or 10 to 14,
. . . , or50 to 54; dose 10 to20. (We tookage at start "less
than 10" as 5-9; likewise, "50 years or older" as 50-54.)
For the ACS volunteers, the data provided to us were
alreadyintheformofacross-tab, with age andyears since
quitfor ex-smokers atbaseline in 1959. The studyperiod
was 1960 to 1965, so we added 4 years toget current age.
For ex-smokers, age at start was not collected.
Byconvention, thenumberofperson-years ineachbasic
cell is treated as a constant inthemodeling. From cell to
cell, the numbers of events are taken as independent.
The expected numberofevents in abasic cellequals the
number of person-years times the hazard rate for that
cell. That is where independence of competing risks
comes in. For example, ifpersons well alongthe progres-
sion toward lung cancer were more susceptible to heart
attacks, survival to age t would change the hazard; how-
ever, by the independence assumption, the hazard does
not change.
When computing the hazardfunction in Equations 1-6,
age and dose are taken as truncated mid-points; for ex-
ample, age 55 to 59 becomes 57, age at start 20 to 24 be-
comes 22, and dose 10 to 19 becomes 15. A dose of40 or
more is taken a bit arbitrarily, as 50.
Our aggregation was chosen to avoid sparse cells and
to treat all three cohorts in a similar way. However, the
procedure puts little emphasis on the response to To,
which is projected out. (Tb maximize the likelihood, only
the sumofthe expecteds needs to be approximatelyright,
not their distribution over To.) Ifthe model is right, the
response to To can be inferred from the response to age
and dose. For the veterans, the model does not do this at
all well (Table 17). Our aggregation may be criticized as
fTble 17. Observed and expected numbers ofevents forthe veterans
by age at start of smoking.
Person-
Age at start years Observed Expected O/E
Less than 10 2,839 11 7 1.6
10-14 32,929 114 79 1.4
15-19 231,146 562 488 1.2
20-24 145,376 308 334 0.9
25-29 37,312 63 96 0.7
30-34 16,070 22 43 0.5
35-39 8,138 6 22 0.3
40 or more 11,490 7 25 0.3
leadingto inefficient procedures; however, they are valid,
and they evidently provide efficient-enough tests.
Models for Animal Data
Introduction
For experimental data on animals, doses are set high,
so the hazard is high, too. The Poisson distribution must
be replaced by the binomial and hazards converted to
probabilities. Theprocess will be illustrated on the mega-
mouse data (27). and the Peto et al. results on skin can-
cer and aging (10) will be considered last.
Mathematical Preliminaries
Let hbe the hazard in amultistage model. With the in-
dependence ofcompetingrisks, theprobability ofan ani-
malgettingcancerduringtheperiodttot + s, conditional
on having survived till the beginning of the period, is
ex J I t }
- - exp(- h(t)s)
[9]
For the current-exposure group in the mega-mouse
study, exposure starts at To = 0, and the formulas for h
become simpler. Consider a model with n precancerous
stages, ofwhich m are potentially sensitive. Suppose To
= 0, and exposure is continuous. Let N be the numberof
targetcells. Assumethe rate ofprogressionthrough stage
iis ai + bi d, when the dose rate is d. The a's andb's must
be nonnegative; stage i is potentially sensitive ifbi is al-
lowed tobepositive; the numberofsuch stages is denoted
m. The hazard rate at time t is essentially asfollows(71):
m tn-I
N rl (ai+bid (n-i)!
Multiplyingtn'l in Equation 10, there is apolynomial in
dose of degree m, with nonpositive roots; and only its
m + 1 coefficients can be estimated. In general, data on
the current-exposure group cannot determine which of
the stages are the sensitive ones, although theirnumber
m canbeestimated, and only certainproducts inthebasic
parameters N, ai, bi can be estimated. Identifiable
parameters canbe obtainedby rewritingEquation 10 as
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h(t) = (co + c1d+ * * +Cmdm) tn-l
where d is dose and t is time. The c's are estimable; t
should be nonnegative, andthe polynomial should hav
nonpositive roots-a constraint which is hard to imp
To capture the constraints, it is possible to factor
dose polynomial, rewriting the hazard rate (Eq. 11)
G[FJ (1 + rjd)]tn1I
The lead constant G is identifiable; and so are the
if arranged in decreasing order. These r's must be i
negative. For Equation 12 to make sense, thebackgrc
rates (the a's in Eq. 10) must be positive.
With ceased exposure, itmatterswhich states are
sitive. To model the mega-mouse data, wewanted to
siderhaving two early stages sensitive. The calculus
out of hand amazingly fast, but a direct computatic
still feasible when the first and second stages are s(
tive. Ifexposure starts at time To = 0 and ends at t
T1, the hazard at a later time t is
At6
+ Bdose [t6- (t-T )6- 6T1(t-TT)5]
+ Cdose [t6 _ (t - T1)6]
+ Ddose2[t6- (t -T - 6TI(t - T,)5]
Here, Arepresents background; B, the sensitivity of
second stage; C, of the first stage; and D, both (4,6)
Mega-Mouse Study
The mega-mouse experiment did not focus on timE
tumor, so the results do not fit naturally into the fra
work of the multistage model. To see the problem n
sharply, take forexample the 336mice assigned to ac
group of 150ppm withplanned sacrifice at 24 monthr
these, 130 survived to 24 months and were sacrifice
thattime; amongthe sacrificed animals, 100hadblad
tumors. The ratio 100/130 represents prevalence, no
cidence. Indeed, it is not known when these tumors
veloped.
To model this data set, we entertained two polar
sumptions: a) The counts represent incidence, tha
tumors which arose during the month of sacrificE
tumors are rarelyfatal, so the counts represent nearl,
the tumors that arose at or before the sacrifice ti
Eitherassumption gives about the same likelihood f
tion for the current exposure group, as will now be
cussed.
The statistical analysis is performed by treating
number ofsurvivors as constant. The counts in the vari-
ous cells are taken to be independentbinomials; the num-
ber oftrials is the number at risk in the cell. Ifassump-
tion a holds, the probability of a mouse getting liver
cancer in month tisgivenbyEquation9, with s = 1 (the
period is viewed as 1 month). Ifassumption b holds, the
probability thatan animal sacrificed attime thas cancer
is
[14] [12] P(,r < t) = 1 - exp I - | h(u)du }
In effect, Equation 14 just increases the number of
ri's, stagesby 1. More specifically, ifh is the hazard rate for,
non- say, a six-stage model with the first and fifth sensitive,
)und then lbh(u) du is the hazardrate for aseven-stagemodel,
again withstages one and five sensitive. Thisfollows from
sen- the usual inductive construction ofh(4,6). Thus, assump-
con- tions aand b turn out to differonlyinthe estimated num-
gets berofstages(forthe current exposuregroupanyway). We
)n is proceed, somewhathesitantly, on the basis ofassumption
ensi- a.
time Data on the mice who diedbefore planned sacrifice are
available on tape, so there is an opportunity for cross-
checking; also see Fanner et al. (29). Combiningdatafrom
sacrifice and spontaneous deaths would require explicit
modeling oflatency, which has been estimated for blad-
der and liver cancer as being about 6 months (72). Such
modeling requires introducing further assumptions,
which seem as drastic in their own way as assumption a.
For other views, see Kalbfleisch et al. (5) or Malani and
van Ryzin (73).
For the current-exposure group in the mega-mouse ex-
[131 periment, the data are reported in a basic two-
dimensional cross-tab fordose x sacrifice time (28). With
the ceased-exposure group there is a third dimension,
namely, the time atwhichexposure ended. The cellcounts the in the basic cross-tab are taken to be independent
binomial variables; in each cell, the event probability is
given by Equation 9 with s = 1, and the number oftrials
is the number of sacrificed animals.
To stabilize theX2, we wanted to avoid sparse cells; nor
e-to- was a sum ofbinomials attractive. Therefore, some dose
tme- x sacrifice groups with low dose or early sacrifice were
tiore eliminatedfromthefitting. Tb some extentthis choicewas
lose data-driven, but it was treated as deterministic in the
S. Of statistical analysis. The impact ofthis move seems to be
,d at small (6). Of course, in Equation 7 for X2, the denomina-
lder tors are the binomial variances.
Itin- BladderTumors. The mega-mouse experiment hadtwo
de- end points, cancers of the bladder and the liver (transi-
tional cell carcinomas ofthe urinary bladder andprimary
r as- hepatocellular carcinomas). The bladder data are shown
Lt is, in Table 18.
3; b) There are a substantial number of responses only at
y all high dose and after long exposure and the hazard in-
ime. creases more rapidly in dose than in time. Carlborg dem-
unc- onstrated this by fitting a Weibull hazard of the form
dis- cdatb, with a > b + 1 (30,31). Justby way ofillustration,
consider thehighriskcurrent-exposure groups inside the
the marked region of Table 18. Fitting the Weibull hazard
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Table 18. Results on bladder cancer from the mega-mouse study: Number ofresponse/number sacrificed (12,13).
Dose, Sacrifice time, months
ppm 9 12 14 15 16 17 18 24 33
0 0/142 0/140 0/113 0/88 0/183 0/127 1/400 1/384 0/24
30 4/1573 0/900 1/92
35 1/389 1/796 2/638 0/45
45 1/271 1/264 1/383 1/445 0/12
60 0/279 2/268 0/224 1/181 0/265 0/206 3/269 3/415 1/11
75 0/139 0/137 0/110 1/94 0/175 0/134 1/267 3/311 4/12
100 1/142 1/138 0/117 0/89 1/90 4/67 5/131 25/160a 8/lOa
150 0/140 9/141 21/114a 28/9Oa 36/85a 36/65a 62/121a 100/130a
aCell used in fitting.
there gives a = 5 and b = 3, roughly. If the rate of in-
crease in dose isfaster thanthe rate in time, Equation 10
cannot hold. On this basis, Carlborg prefers the Weibull
to the multistage. However, the values for a and b are
quite sensitive to the cells used in fitting. Furthermore,
the Weibull did not fit even the handful of cells marked
in Table 18, which represents a third cut at fitting pro-
gressively smaller portions of the data.
We also tried on the high-risk cells four- or five-stage
models with all stages sensitive: a = 4 and b = 3, or a =
5 and b = 4. The former is better, but does not fit even
the selected cells, havingX2 = 22 on 7 degrees offreedom.
Also, the multistage model predicts 197 cancers in the
censored cells (outside the marked region) with 55 ob-
served; the Weibull model does about the same. In short,
neither the Weibull nor the multistage fits.
Brown and Hoel(12) say ahazardis "factorable" if, like
the multistage hazard in Equation 10, it is a function of
dose x a function oftime. They argue that no factorable
hazardfunction will fit thewhole data set. Transforming
the dose scale does not affect factorability and therefore
will notmake the modelfit. The sparseness ofmostofthe
cellsinthe table maynotaffecttheiranalysis toomuch(6).
Liver Tumors. For liver tumors too, the current-
exposure group seemed the natural starting point. To
stabilize the behavior ofthe X2 statistic, it seemed advan-
tageous to developthemodels only onpartofthe data set,
censoringthe sparse cellswithlowdose orearlysacrifice.
(For each dose group, we started with the longest ex-
posures, and cut backuntil cellswith two events orfewer
were encountered.)
The models had grotesque chi-squareds, and the
residuals showed mostoftheproblem to comefrom a dose
of60 ppm and sacrifice at 24 months. Afterlooking more
closely at the data source (28) we convinced ourselves that
there was a misprint in that cell, which reports 7/415
events, and an incidence rate of 17.1%. The rate looks
plausible, and we changed the numerator to 0.171 x 415
= 71, agreeing with (13).
Table 19 shows the corrected data; cells used in fitting
are inside the marked region; 27/621 events are censored
(outside theregion). We wentahead onthe corrected data,
fitting models with hazard rates defined by Equation 11
without the constraint ofnonpositive roots, or by Equa-
tion 12 with all constraints imposed. The constraints in
Equation 11 are seldomimposed, soitis worth consider-
ing what happens without them. Ib illustrate, suppose
n = 7 and m = 2 so there are seven stages ofwhich two
are sensitive. Equation 11 gives the model
155 + 588d + 896d2,
142(1 +2.38d)2,
x2 = 26.3 , Ilrs = 26.2.
Lr14a]
X2 = 26.7, lrs = 26.5
[14b]
lrs is the Neyman-Pearson likelihood ratio statistic of
Equation 8, while X2 is defined by Equation 7 with the
binomial variances in the denominators. Equation 11 fits
alittlebetterbutthepolynomial hasimaginary roots. The
double root from Equation 12 seems unlikely; however,
the discriminant ofthequadratichasbeenprevented from
going negative and an end point maximum occurs when
the latter vanishes. In sum, fitting the polynomial with-
out constraints does not lead to a proper multistage
model.
Table 20 reports the results offittingmultistage models
ofthe form ofEquation 12 to the liver tumor data in the
Table 19. Results on liver cancer from the mega-mouse study: Number ofresponse/number sacrificed (12,13,27).
Dose, Sacrifice time, months
ppm 9 12 14 15 16 17 18 24 33
0 0/142 0/140 0/113 0/88 1/183 0/128 1/401 9/383a 8/23a
30 17/1573a 55/900a 44/92a
35 2/389 7/792a 55/639a 20/45a
45 2/272 5/264a 7/383a 57/445a 5/12a
60 0/279 2/268 0/224 1/182 4/265a 6/206a 7/268a 71/415a 7/lla
75 0/139 0/137 0/110 1/94 5/174a 5/134a 6/267a 62/311a 8/12a
100 1/142 3/138 1/117 4/90 1/90 1/67 6/131a 47/160a 8/lOa
150 0/140 1/141 1/114 1/90 3/86 0/65 7/121a 56/130a
aCell used infitting.
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Table 20. Results for the mega-mouse study: Continuous exposure to 2-AAF and resulting liver tumorsa
n m df X2 G r, r2 r3 Comment
6 1 25 72 27 11 Does not fit
6 2 24 53 37 2.2 2.2 Does not fit
6 3 23 53 37 2.2 2.2 0.00 Does not fit
7 1 25 48 104 12 p < 5/1000
7 2 24 27 142 2.4 2.4 Fits, p = 30%
7 3 23 27 142 2.4 2.4 0.00 Fits, p = 26%
8 1 25 64 386 14 Does not fit
8 2 24 39 518 2.6 2.6 Marginal fit, p = 3%
8 3 23 39 518 2.6 2.6 0.00 Marginal fit, p = 2%
9 1 25 133 1391 15 Does not fit
9 2 24 109 1789 3.0 3.0 Does not fit
9 3 23 109 1815 2.9 2.9 0.02 Does not fit r4
9 4 22 109 1815 2.9 2.9 0.02 Does not fit r4 = 0
aA seven-stage model fits the data, with two stages sensitive. The parameters express the hazard function (Eq. 12) as a function of d = (dose in
ppm) /100 and t = (time in months) /100. Parameters estimated as 0 are recorded as 0.00.
current exposure group; reported cancers are treated as
incident. The Fisherinformation matrix usually cannotbe
inverted for these models, so standard errors are not
reported. For a simulation study on the accuracy ofthe
MLE's andthe minorimpactofcensoring, see Freedman
and Navidi (6).
The data can be fitted by amultistage model with seven
stages, ofwhich two are sensitive; we saw no pattern in
the residuals. Since exposure starts atbirth, the data on
the current-exposure group cannot determine which two
stages out ofthe seven are the sensitive ones. There are
T2 = 21 models to explore, and it was easiest to begin
with the mostfamiliar: Equations 1,2, and3withthefirst
and sixth stages sensitive. This is connected with Equa-
tion 12 as follows:
A = G, B = Gr1
C = Gr2, D = Grl r2 [15]
A = G, B = Gr2,
C = Grl, D = Gr1r2 [16]
In the present application, r1 and r2 are estimated as
equal, so the two models coincide. Onthe ceased-exposure
group, this model gave X2= 100 on 24 degrees offreedom.
Examination ofthe residuals showed that most wereposi-
tive; predicted risk was too low after exposure ended.
This suggestedtrying amodel with two early stages sen-
sitive, rather than one early and one late: Equation 13.
The coefficients in Equation 13 canbeobtained asabove
from Equations 15 and 16, giving A = 142, B = C = 338,
and D = 803. This time, the model fits the ceased-
exposure group: x = 30 on 24 degrees offreedom (p =
18%), although the residuals suggest thatpredicted risk
is too low at longer sacrifice times. (Since the choice of
model was data-driven, the p-values are no longer pro-
tectedbycross-validation, and are biased toward accept-
ingthe model.) Almost as an afterthought, we wentback
to the omitted cells with low dose or early exposure (Ta-
ble 19). There were 27 events in these cells, with a
predicted 41. This looks bad, but the censored observa-
tions tend to be the smaller ones. The bootstrap assigns
a p-value of 14% to a test based on the statistic
"predicted-observed" for the censored cells (6).
We then looked at the eight-stage model with first and
second stages sensitive. This was marginal on the main
group of cells, and looked fine on the censored ones (26
predicted, 27 observed, although the bias is still there).
The model did notfit the ceased-exposure group (X2 = 41
on 24 degrees offreedom). Again, the residuals were too
positive.
Brown and Hoel
Brown and Hoel (13)fit amultistage model to the liver
data. We fully agree with their conclusion:
The way in which dose isrepresented in the model maybe very
consequential, and [this] illustrates the basic difficulties one may
encounter when attempting to concludewith confidence anything
about the initiation/promotion mechanisms based on tumor count
data.
Ingeneral termns, ourresults are consistentwith theirs,
but there are some points ofdisagreement: we like seven
stages with two sensitive, they like six stages with one
sensitive, orfour with two sensitive. They seem to be fol-
lowing assumption b and Equation 14, so seven of our
stages correspond to six oftheirs; however, we cannot fit
a seven-stage model with one sensitive, or a five-stage
model with two sensitive.
One reason for the discrepancies seems to be Brown
and Hoel's decision to eliminate the group sacrificed at33
months, based on examination ofresidual plots; the plots
may show the heterogeneity we picked up in cross-
validation. Another reason is the choice of functional
form: they include a constant latency parameter, make a
nonstandard adjustment forbackground, and have a dose
threshold effect.
We are usingx2 = I (obs-exp)2/var, Brownand Hoel are
using Irs. However, by our reckoning, fitting the seven-
stage model with two stages sensitive on all 56cells gives
lrs = 64 or x2 = 65, with 53 degrees offreedom, so this
may not matter. On the interpretation in the presence of
sparse cells, see Freedman and Navidi (6). The estimated
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r's from fitting to all 56 cells were quite different from
those in Table 20, being 3.32 and 1.56, respectively; G was
about the same, at 141.
Peto Mice
Peto et al, report on an experiment with four treatment
groups, benzpyrene being applied starting at 10 weeks,
25 weeks, 40 weeks, and 55 weeks (10). Peto et al. chart
the tumors fortnightly, and Table 21 reproduces some of
the data from their Appendix for weeks ofbenzpyrene 40
through 58.
As we understand it, the first line in the table reports
the number of tumors that developed during the weeks
39 and 40 oftreatment and were charted at week40; this
line also reports the corresponding number ofanimals at
risk. In group 1, there were no tumors and 130 animals
at risk, and so forth. We did not use data prior to chart-
ing at week 40 or after week 90 when the cells get very
sparse.
For group 3 and week 54, there seems to be a
typographical error (10) which is noted in Table 21;
presumably, the number ofanimals at riskis 166, not 116,
and we have used 166 in the analysis below. The data are
collapsed as shown in Table 22: for group 1, the number
oftumors appearing at weeks 40, 42, ... , 50 is 0 + t ...
+ 2 = 8, and the number atriskis 130 + 128 + ... + 121
753. The other entries in Table 22 are similar.
The counts in the pooled cells are modeled as binomial,
the number of trials being the sum of the number of
animals at risk in the basiccells, as shown in Table22, and
the probability of an event is the average ofthe probabil-
ities given by Equation 9, weighted by the numbers at
risk; time t is measured in weeks, and s = 2 (a fortnight
is 2 weeks). This procedure seems togive a reasonable ap-
proximation to a sum ofindependent binomials, since the
multistage probabilities do not change much from fort-
night to fortnight. IfXi are independent binomials with
Nitrials and event probability pi, and the pi are not too
variable, then Xi + X2 is approximately binomial with N1
+ N2 trials and event probability p = (Nip, + N2p2) I (N1
+N2).
In this study, there was only one dose group; the units
are chosen so dose = 1, and then dose 2 = dose. The C and
D terms in Equations 1-3 collapse, so only A, B, C + D
can be estimated. Since AD = BC, the separate coeffi-
cients C and D can be determined if all are positive.
The results are shown in Table 23 and suggest A = B
= 0, soC and D are not estimated separately. The numer-
ical algorithm we used would not maximize the likelihood
function with the constraint that all coefficients be non-
negative, so negative values are allowed. The parameter
estimates are so close to the boundary that the Fisher
standard errors are not reliable; however, standard errors
can be obtained by the bootstrap.
The model has been fitted to only one dose group and
predicts no background, for A and B are negligible. This
is impressive. The interpretation of zeros: If A = B = D
Table 21. Data from Peto et al. (10) for weeks 40 to 58.
Group 1 Group 2 Group 3 Group 4
Weeks of (BP from age (BP from age (BP from age (BP from age
benzpyrene 10 weeks) 25 weeks) 40 weeks) 55 weeks)
40 0/130 0/154 1/292 1/311
42 1/128 1/154 0/190 1/303
44 1/126 0/150 1/187 3/296
46 2/125 2/149 0/182 2/286
48 2/123 5/146 1/181 2/275
50 2/121 0/141 0/176 3/265
52 6/119 4/141 2/172 1/255
54 2/113 3/137 1/116a 6/239
56 3/111 4/130 4/162 9/222
58 10/108 4/126 4/154 10/203
aThis is aprobable typographical error: The number of mice at risk cannot drop from 172 to 116 and then go back up to 162.
Table 22. Peto mice: Observed skin cancers/numbers at risk.
Weeks of Age at start of exposure, weeks
benzpyrene 10 25 40 55
40-50 8/753 8/894 3/1108 12/1736
52-54 8/232 7/278 3/338a 7/494
56-58 13/219 8/256 8/316 19/425
60-62 13/187 16/229 12/286 26/345
64-66 12/162 15/188 20/239 18/243
68-70 16/132 27/150 16/184 21/175
72-74 15/95 14/96 15/139 13/118
76-78 5/68 13/67 16/93 7/76
80-82 7/51 6/43 7/65 8/36
84-88 9/31 11/36 12/58 2/33
aA probable error has been corrected.
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Table 23. Results for the Peto mice.a
n A B C+D x2 Comment
5 -3 -4 251 77 Does notfit
6 14 -18 350 67 Does not fit,
p = 2/1000
7 34 -35 481 81 Does not fit
8 68 -67 651 117 Does not fit
aThere are 37 degrees offreedom in the X2. The hazard is per week,
and the coefficients should be divided by 102n+ 1.
= 0 and C > 0, the first stage is the only sensitive one
and the only one with no background rate. IfA = B = C
= 0 and D > 0, then the first and next-to-last stages are
sensitive but have no background rates; the other stages
have positive background rates. If A = B = 0 but C >
0and D > 0, then thefirstandnext-to-last stagesare sen-
sitive; all stages but the first have positive background
rates (6). Ifthe first and next-to-last stages areboth sen-
sitive, the dose response would be quadratic: Peto et al.
were concernedwhethertheirresultsare compatible with
quadratic dose response (10).
Partly on biological grounds by mainly on statistical
ones, Peto et al. adopted a 28-week latency period be-
tween the transition to the cancerous state for a cell and
the appearance ofa tumor. As a result, they fit a hazard
rate of the form (duration - 28)3, that is, a four-stage
model. We do not use the lag, and find a six-stage model
gives the best fit, with a x2 = 67 on 37 degrees offree-
dom; the lagged model fits a little better with x2 = 60.
Results might be cross-validated on data in Lee and
O'Neill (74).
The large values ofX2 inTable 23 aremainly due to two
or three cells, where the differences between observed
and expected are substantial. This couldhavebeen anar-
tifact of the aggregation. So we reaggregated, making
some effort to eliminate the discrepancies. (The second
pooling: 40-52, 54-56, 58-60, 62-64, 66-68, 70-72, 74-76,
78-80, 82-84, 86-88.) The estimated coefficients stayed
about the same, but the X2 only dropped imperceptibly,
from 67to 64. The incidence rates are sufficiently irregu-
lar that we stopped trying to fit models.
Peto et al. are trying to show that cancer results from
the duration of exposure to the carcinogen, rather than
the effect oftime per se. The experiment and the associ-
ated arguments are interesting but hardly conclusive,
even settingaside the question ofwhether the modelfits
the data.
In the multistage framework, the rate of progression
through the stages depends on dosebut nottime andthat
seems to be a criticalpoint inthe argument. If, for exam-
ple, the rate of progression through a stage really was
time-dependent, Peto et al. might agree that time per se
plays arole in carcinogenesis. Butthe stages inthemodel
are not experimentally identified; so we can produce a
modelwhere one stage has atime-dependent hazard rate,
and the overall hazard rate is exactly the same as in the
bestmultistage model. In short, ifthe stages are notiden-
tifiable, neither is the duration versus age issue. Tb fin-
ish the argument we putup the multistage model and the
alternative.
The best-fittingmultistage model (with no latency, A =
B = 0) is of the form
(C dose + D dose2) duration5
This corresponds to a six-stage model, inwhichtheback-
ground rate for the first stage vanishes; the first stage
and possibly the fifth are sensitive; hazard rates for the
six stages do not depend on time. For now, call this the
"C - D model.'
Consider next an alternative model with four stages:
Thefirst stage hasthe samehazardrateasthefirst stage
in the C - D model; the third stage has the same hazard
rate asthefifth stage inthe C - Dmodel; thefourth stage
has the same hazard rate as the sixth stage in the C - D
model; the remaining second stage has atime-dependent
hazard rate, h (t) = constant t2.
In this alternative model, a cell starts to age only after
it has been moved out of stage one by the benzpyrene,
which is not so far-fetched, given that Peto et al. are
studying atumorthat does not occur spontaneously. The
hazardrateinthe second stageistime-dependent, sotime
per se plays a role in carcinogenesis. In short, no argu-
ment about the effect of time itself seems likely to suc-
ceed until the stages are better defined.
The alternative modelmay seem artificial, but no more
sothanthemultistage modelitself. The construction may
also promptthe question, Why shouldthe hazardrate be
time-dependent? However, insistingon multistage models
with hazard ratesbe depending only on dose is simply to
decide the question ofage versus duration on an apriori
basis.
Technical Details
Fisher Standard Errors
Let L (XI@) be the likelihood of the data X given the
vector of parameters E. The Fisher information matrix
I(o) is defined as
I(e) -E a2logL(X I e)
aE92 J[16a]
The expected value is computed with respect to E.
Asymptotically, the inverse of I(e) gives the variance-
covariance matrixofthe MLE, at E. Ordinarily, the MLE
e will be substituted for E, to get a sample-based esti-
mate The FisherSEs are the square rootsofthediagonal
elements of I(e)-1. In particular, these can be computed
from the data; the unknown parameter is not involved.
Observed information may also be used.
Regularity conditions aregiven in Lehmann(36), for ex-
ample, and exclude cases where E falls on the boundary,
corresponding to 0'sfor B or C inthepresentapplication.
For somepositiveresults ontheboundary, seeFreedman
and Navidi (6).
The matrix I(o) is nonnegative definite, but not neces-
sarilypositive definite. Withthe mega-mouse liver data,
atthe MLE6, wefound I(E1)toberank-deficient, suggest-
ing a singular distribution for 6.
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Computational Details
Most ofthe computerworkwas done in FORTRAN on
a VAX 750, with many ofthe calculations replicated some-
what independently in True BASIC on an IBM PC-XT. A
few were replicated quite independently by Duncan
Thomas at USC, but this does not imply that he agrees
(or disagrees) with our conclusions.
Ti findthe maximum ofthe loglikelihoodfunction, we
used a computerroutine written by NAG (Numerical Al-
gorithm Group). This starts searching from a given ini-
tialpoint; it eitherreportsfailure to converge orfindsthe
maxium. Usually, as best we can tell, it does find the
global maximum; occasionally, itisfooledby alocal max-
imum.
The algorithm was started from several points to see if
there were multiple maxima and derivatives ofthe likeli-
hood function were checked at each reported value to
make sure this was at least a local maximum. In almost
allthe data sets described above, the algorithmfoundonly
one value, which we believe to be the global maximum.
There was anexception: infittingall 56cells ofthemega-
mouse liver data, NAG's first pick was a saddle point on
the line ri = r2.
Wethank K. Brown,J. Cairns, M. Eaton, B. Efron, L. Garfinkel, P. Lee,
S. Moolgavkar, D. Petitti, M. Pike, J. Robins, S. Swan, D. Thomas, and
A. Whittemore for their help. The American Cancer Society, the Na-
tional Cancer Institute, and the National Center for Ibxicological Re-
search kindly provided data. Our research was partially supported by
NSF grant DMS 86-01634.
REFERENCES
1. Armitage, P., and Doll, R. Stochastic models forcarcinogenesis. In:
Proceedings ofthe Fourth Berkeley Symposium on Mathematical
Statistics andProbability, Vol. IV(L. LeCam andJ. Neyman, Eds.),
University of California Press, Berkeley, CA 1961, pp. 19-38.
2. U.S. Environmental Protection Agency. Guidelines forcarcinogenic
risk assessment. Fed. Reg. 51: 33992-34003 (1986).
3. Borszonyi, M., Day, N. E., Lapis, K., and Yamasaki, H., Eds.
Models, Mechanisms and Etiology ofTumour Promotion. Interna-
tional Agency for Research on Cancer, Scientific Publication,
No. 56, Lyon, France, 1984.
4. Whittemore, A., andKeller, J. Quantitative theories ofcarcinogen-
esis. SIAM Rev. 20: 1-30 (1978).
5. Kalbfleisch, J. D., Krewski, D. R., and van Ryzin, J. Dose-response
models fortime-to-response toxicity data. Can. J. Stat. 11: 25-45
(1983).
6. Freedman, D., and Navidi, W. On the Multistage Model for Car-
cinogenesis. Technical Report No. 97, Department ofStatistics, Uni-
versity ofCalifornia, Berkeley, CA, 1987.
7. Moolgavkar, S. H. Themultistage theory ofcarcinogenesis and the
age distribution ofcancer in man. J. Natl. Cancer Inst. 61: 49-52
(1978).
8. Cook, P. J., Doll, R., and Fellingham, S. A. A mathematical model
forthe age distribution ofcancerin man. Intl. J. Cancer4: 93-112
(1969).
9. Doll, R., andPeto, R. Cigarette smokingandbronchial carcinoma
amongregular smokers andlifelongnon-smokers. J. Epidemiol. and
Commun. Health 32: 303-313 (1978).
10. Peto, R., Roe, F. J. C., Lee, P. N., Levy, L., and Clack, J. Cancer
and ageing in mice and men. Br. J. Cancer 32: 411-426 (1975).
11. Peto, J., Seidmann, H., and Selikoff, I. J. Mesotheliomamortality
in asbestos workers: Implications formodels ofcarcinogenesis and
risk assessment. Br. J. Cancer 45: 124-135 (1982).
12. Brown, K. G., and Hoel, D. G. Modeling time-to-tumor data: Anal-
ysis ofthe ED01 study. Fundam. Appl. Ibxicol. 3:458-469 (1983).
13. Brown, K. G., and Hoel, D. G. Multistage prediction of cancer in
serially dosed mice with application to the ED01 study. Fundam.
Appl. Ibxicol. 3: 470-477 (1983).
14. Ames, B. N.,Magaw R., andGold, L. Rankdngpossible carcinogenic
hazards. Science 236: 271-279 (1987).
15. Bishop, J. M. The moleculargenetics ofcancer. Science 235: 305-311
(1987).
16. Freedman, D., and Zeisel, H. From mouse to man: The quantita-
tive assessment of cancer risks. Statist. Sci. 3: 3-56 (1988).
17. Kaldor, J. M., and Day, N. E. Interpretation of Epidemiological
Studies inthe Context oftheMultistage Model ofCarcinogenesis.
Technical Report, International Agency for Research on Cancer,
Lyon, 1986.
18. Moolgavkar, S. H. Carcinogenesis modeling: From molecular biol-
ogy to epidemiology. Annu. Rev. Public Health 7: 151-169 (1986).
19. Bodmer, W F., Bailey, C. J., Bodmer, J., Bussey, H. J. R., Ellis, A.,
Gorman, P., Lucibello, F. C., Murday, V. A., Rider, S. H.,
Scambler, P., Sheer, D., Solomon, E., and Spurr, N. K. Localization
ofthe gene forfamilial, adenomatous polyposis on chromosome 5.
Nature 328: 614-616 (1987).
20. Naylor, S. L., Johnson, B. E., Minna, J. D., and Sakaguchi, A. Y.
Loss ofheterozygosity ofchromosome 3p markers in small-cell lung
cancer. Nature 329: 451-454 (1987).
21. Solomon, E., Voss, R., Hall, V., Bodmer, W F.,Jass, J. R.,Jeffreys,
A. J., Lucibello, F. C., Patel, I., and Rider, S. H. Chromosome 5 al-
leleloss inhuman colorectal carcinomas. Nature328: 616-619(1987).
22. Brown, C. C., and Chu, K. Use ofmultistage models to infer stage
affected by carcinogenic exposure: Example oflungcancerand cig-
arette smoking. J. Chron. Dis. 40 (suppl.) 2: 171S-179S (1987).
23. Kahn, H. A. The Dorn studyofsmoking and mortality among US
veterans: Report on eight and one-half years of observation. In:
Epidemiological Approaches to the Study of Cancer and Other
Chronic Diseases (W. Haenszel, Ed.), National Cancer Institute
Monograph No. 19, Washington, D.C. 1969, pp. 1-126.
24. Rogot, E. Smoking and mortality among US veterans. J. Chron.
Dis. 27: 189-203 (1974).
25. Whittemore, A. Effect of cigarette smoking in epidemiological
studies oflung cancer. Stat. Med. 7: 223-238 (1988).
26. Hammond, E. C. Smokinginrelation to the death rates ofone mil-
lionmenandwomen. In: Epidemiological Approaches tothe Study
ofCancer and Other Chronic Diseases (W. Haenszel, Ed.), National
Cancer Institute Monograph No. 19, Washington, D. C. 1969, pp.
127-204.
27. Staffa, J. A., andMehlman, M. A., Eds. Innovations in Cancer Risk
Assessment (ED01 study). J. Environ. Pathol. Ibxicol. 3: 1-246
(1980).
28. Littlefield, N. A., Farmer, J. H., Gaylor, D. W., and Sheldon, W. G.
Effectsofdose andtimeinalong-term, low dose carcinogenic study.
J. Environ. Pathol. Ibxicol. 3: 17-34 (1980).
29. Farmer, J. H., Kodell, R. L., Greenman, D. L., and Shaw, G. W.
Dose and time response models for the incidence ofbladder and
liver neoplasms in mice fed2-acetylaminofluorene continuously. J.
Environ. Pathol. Toxicol. 3: 55-68 (1980).
30. Carlborg, F. W Multistage dose response models in carcinogene-
sis. Fd. Cosmet. Toxicol. 19: 361-365 (1981).
31. Carlborg, F. W 2-Acetylaminofluorene and the Weibull model. Fd.
Cosmet. Toxicol. 19: 367-371 (1981).
32. Peto, R., Parish, S. E., and Gray, R. G. There is no such thing as
ageing, and cancer is not related to it. In: Age-Related Factors in
Carcinogenesis (A. Likhachev, V. Ansimov, and R. Montesano,
Eds.), International Agency for Research on Cancer, Scientific Pub-
lication No. 58, Lyon, France, 1986, pp. 43-53.
33. Peto, R., Gray, R., Brantom, R, and Grasso, P. Nitrosamine carcino-
genesis in 5120rodents. In: N-Nitroso Compounds: Occurrence, Bi-
ological Effects and Relevance to Human Cancer (J. K. O'Neill,
R. C. von Borstel, C. T. Miller, J. Long, and H. Bartsch, Eds.), In-
ternational Agency for Research on Cancer, Scientific Publication
No. 57, Lyon, 1984, pp. 627-665.
34. Drew, R. T., Boorman, G. A., Haseman, J. K., McConnell, E. E.,
Bosey, W. M., and Moore, J. A. The effect ofage and exposure du-
ration on cancerinduction by aknown carcinogen in rats, mice, and188 FREEDMAN AND NAVIDI
hamsters. Toxicol. Appl. Pharmacol. 68: 120-130 (1983).
35. Ames, B. N. Measuring Oxidative Damage in Humans: Relation
to Cancer and Aging. Tlchnical Report, Department ofBiochemis-
try, University of California, Berkeley, CA.
36. Lehmann, E. Theory of Point Estimation. Wiley and Sons, New
York, 1983.
37. Lehmann, E. Testing Statistical Hypotheses, 2nd ed. Wiley and
Sons, New York, 1986.
38. Kalbfleisch, J. D., and Prentice, R. L. The Statistical Analysis of
Failure Time Data. Wiley and Sons, New York, 1980.
39. Rao, C. R. Linear Statistical Inference and its Applications, 2nd
ed. Wiley and Sons, New York, 1973.
40. Pearl, R. Ibacco smokingandlongevity. Science 87:216-217(1938).
41. Stevens, R. G., andMoolgavkar, S. H. A cohort analysis oflung can-
cer and smokingin British males. Am. J. Epidemiol. 119: 624-641
(1984).
42. Peto, R. Epidemiology, multistage models, and short-term mutage-
nicity tests. In: Origins ofHuman Cancer, BookC(H. H. Hiatt, J.
D. Watson, andJ. A. Winsten, Eds.), Cold SpringHarbor Labora-
tory, Cold Spring Harbor, NY, 1977, pp. 1403-1428.
43. Doll, R., and Peto, R. The causes of cancer. J. Natl. Cancer Inst.
66: 1191-1309 (1981).
44. Wald, N.J., and Doll, R., Eds. Interpretation ofNegative Epidemi-
ological Evidence for Carcinogenicity. International Agency for Re-
search On Cancer Scientific Publication No. 65, Lyon, 1985.
45. Armitage, P. Multistage models ofcarcinogenesis. Environ. Health
Perspect. 63: 195-201 (1985).
46. Lave, L. B. Health and safety risk analyses: Information for bet-
ter decisions. Science 236: 291-295 (1987).
47. Vouk, V. B., Hoel, D. G., Butler, G. C., Peakall, D. B., Eds. Methods
forEstimating Risk ofChemical Injury: Human and Non-Human
Biota and Ecosystems. Wiley and Sons, New York, 1985.
48. Zeise, L., Wilson, R., and Crouch, E. A. C. Dose response relation-
ships for carcinogens: A review. Environ. Health Perspect. 73:
259-308 (1987).
49. U.S. Public Health Service. Saccharin and its salts: Proposed rule
making. Report ofthe Food and Drug Administration. Fed. Reg.
42: 19996-20010 (1977).
50. National Academy of Sciences. Saccharin: Technical Assessment
of Risks and Benefits. Washington, DC, 1978.
51. Aalen, 0. 0. Nonparametric inference for afamily ofcountingpro-
cesses. Ann. Stat. 6: 701-726 (1978).
52. Jacobsen, M. Statistical Analysis ofCounting Processes. Springer-
Verlag, New York, 1982.
53. Moolgavkar, S. H., and Venzon, D. J. Confidence regions in curved
exponential families: Applications to matched case-control and sur-
vival studies with general relative risk function. Ann. Stat. 15:
346-359 (1987).
54. Moolgavkar, S. H., and Venzon, D. J. Curvature, Biasand Diagnos-
tics: Application to Relative Risk Regression Models. Technical Re-
port, Fred Hutchinson Cancer Research Center, Seattle, WA, 1987.
55. International Agency for Research on Cancer. Ibbacco Smoking.
Monograph 38. International Agencyfor Research onCancer, Lyon,
France, 1986.
56. Peto, J. Early- andlate-stage carcinogenesisin mouse skin and man.
In: Models, Mechanisms and Etiology of Tumour Promotion (M.
Borszonyi, N. E. Day, K. Lapis, and H. Yamasaki, Eds.), Interna-
tional Agency for Research on Cancer, Scientific Publication No.
56, Lyon, France, 1984, pp. 359-372.
57. Doll, R. Practical steps towards the prevention ofbronchial carci-
noma. Scot. Med. J. 15: 433-447 (1970).
58. U.S. Public Health Service. Smoking and Health. Report ofthe ad-
visory committee to the Surgeon General ofthe Public Health Ser-
vice. Department ofHealth, Education and Welfare, Washington,
DC, 1979.
59. Wynder, E. L., and Hecht, S., Eds. Lung Cancer. UICC Technical
Report Series, Vol. 25, Geneva, 1976.
60. Doll, R., and Peto, R. Mortality in relation to smoking: 20years ob-
servations on male British doctors. Br. Med. J. 2: 1525-1536 (1976).
61. Lubin, J. H., Blot, W. J., Berrino, F., Flamant, R., Gillis, C. R.,
Kunze, M., Schmahl, D., and Visco, G. Modifying risk ofdevelop-
inglung cancerby changing habits ofcigarette smoking. Br. Med.
J. 288: 1953-1956 (1984).
62. McKenzie, I., and Rous, P. The experimental disclosure of latent
neoplastic changes in tarred skin. J. Exp. Med. 73: 391-416(1941).
63. Hennings, H., Shores, R., Wenk, M. L., Spangler, E. F., Tarone, R.,
and Yuspa, S. H. Malignant conversion ofmouse skin tumours is
increased by tumour initiators and unaffected by tumour
promoters. Nature 304: 67-68 (1983).
64. Farber, E., and Sarma, D. S. R. Hepatocarcinogenesis: A dynamic
cellular perspective. Lab. Invest. 56: 4-22 (1987).
65. Freedman, D., and Navidi, W. Ex-Smoker and the Multistage
Modelfor LungCancer. Technical Report No. 135, Department of
Statistics, University ofCalifornia, Berkeley, CA 1988.
66. Gaffney, M., and Altshuler, B. An examination ofthe role ofciga-
rette smoke in lung carcinogenesis using multistage models. Tech-
nical report. JNCI 80: 925-931 (1988).
67. Geddes, D. M. The natural history oflung cancer: A review based
on rates of tumor growth. Br. J. Dis. Chest 73: 1-17 (1979).
68. Weiss, W. Implications oftumor growth for the natural history of
lung cancer. J. Occup. Med. 26: 345-352 (1984).
69. Tiatis, A. A nonidentifiability aspect oftheproblem ofcompeting
risks. Proc. Natl. Acad. Sci. (U.S.) 72: 20-22 (1975).
70. Frome, G., and Checkoway, H. Use of Poisson regression models
in estimating incidence rates and ratios. Am. J. Epidemiol. 121:
309-23 (1985).
71. Day, N. E., and Brown, C. C. Multistage models and primary
prevention of cancer. J. Natl. Cancer Inst. 64: 977-89 (1980).
72. Kodell, R., Farmer, J. H., and Greenman, D. L. Estimation ofdis-
tribution oftime to appearance of tumor and time to death from
tumor after appearance oftumor in mice fed2-acetylaminofluorene.
J. Environ. Pathol. Toxicol. 3: 89-102 (1980).
73. Malani, H., and van Ryzin, J. Nonparametric Estimates ofthe Tu-
mor Incidence Rate, the Tumor Lethality Rate and the Mortality
Rate in Absence of Tumors in Animal Carcinogenicity Experi-
ments. Technical Report No. B56. Division ofBiostatistics, Colum-
bia University, New York, 1986.
74. Lee, P. N., and O'Neill, J. A. The effect both oftime and dose ap-
plied on tumourincidence rate inbenzopyrene skin painting experi-
ments. Br. J. Cancer 25: 759-770 (1971).